ReviewCurrent opinion in nephrology and hypertension2013
Role of leptin and central nervous system melanocortins in obesity hypertension.
Review in Current opinion in nephrology and hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 62 citations in OpenAlex.
- Efficacy of nebivolol-valsartan single-pill combination in obese and nonobese patients with hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2017Trial
- Developmental Programming of Kidney Disease Across the Life Course: A Narrative Review Focused on Inflammation.International journal of molecular sciences · 2026Review
- Obesity Biomarkers: Exploring Factors, Ramification, Machine Learning, and AI-Unveiling Insights in Health Research.MedComm · 2025Review
- Sex differences in the sensitization of prenatally programmed hypertension.Frontiers in physiology · 2025Review
- Chronic central nervous system leptin administration attenuates kidney dysfunction and injury in a model of ischemia/reperfusion-induced acute kidney injury.American journal of physiology. Renal physiology · 2024Article
- Angiotensin in the Arcuate: Mechanisms Integrating Cardiometabolic Control: The 2022 COH Mid-Career Award for Research Excellence.Hypertension (Dallas, Tex. : 1979) · 2024Review
- Brain Dopamine-Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects.International journal of molecular sciences · 2023Review
- Sugar, salt, immunity and the cause of primary hypertension.Clinical kidney journal · 2023Review
- Soluble (Pro)Renin Receptor in Hypertension.Nephron · 2023Review
- Impact of hyperleptinemia during placental ischemia-induced hypertension in pregnant rats.American journal of physiology. Heart and circulatory physiology · 2021Article
- Role of the Melanocortin System in the Central Regulation of Cardiovascular Functions.Frontiers in physiology · 2021Review
- High-fat diet from parental generation exaggerates body and adipose tissue weights in pregnant offspring.PloS one · 2020Article
- Role of melanocortin 4 receptor in hypertension induced by chronic intermittent hypoxia.Acta physiologica (Oxford, England) · 2019Article
- Cancer and comorbidity: The role of leptin in breast cancer and associated pathologies.World journal of clinical cases · 2018Review
- Review
- Astragaloside IV Prevents Obesity-Associated Hypertension by Improving Pro-Inflammatory Reaction and Leptin Resistance.Molecules and cells · 2018Article
- Role of the brain melanocortins in blood pressure regulation.Biochimica et biophysica acta. Molecular basis of disease · 2017Review
- Neural Programmatic Role of Leptin, TNFα, Melanocortin, and Glutamate in Blood Pressure Regulation vs Obesity-Related Hypertension in Male C57BL/6 Mice.Endocrinology · 2017Article
- Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women.Current hypertension reports · 2017Review
- Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome.Journal of nature and science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewObesity is a major worldwide health problem. Excess weight gain is the most significant preventable cause of increased blood pressure (BP) in patients with essential hypertension and increases the risk for cardiovascular and renal diseases. Our goal is to review the mechanisms that link obesity with hypertension, with special emphasis on the role of leptin and the brain melanocortin system in driving sympathetic activation in obesity. RECENT
findingsDespite increased interest in obesity as a major risk for developing hypertension, the precise mechanisms linking excess weight gain with increases in BP are still elusive. Current evidence suggests that increased sympathetic nervous system (SNS) activity contributes to impaired renal-pressure natriuresis and sodium retention in obesity. Recent findings indicate that the adipocyte-derived hormone, leptin, activates brain centers that regulate SNS activity through a melanocortin-system-dependent pathway. The interaction of leptin and the brain melanocortin system represents an important area of research to further our understanding of the mechanisms leading to sympathetic activation in obesity. SUMMARY: Sympathetic overactivity is an important link between excess weight gain and increased BP. Hormones and cytokines secreted by the adipose tissue that interact with neural pathways (e.g. melanocortin system) appear to play a key role in contributing to sympathetic activation in obesity and represent potential new targets for therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.